scholarly journals Cystic fibrosis heterozygosity does not impact ovarian reserve or assisted reproductive technology outcomes

2019 ◽  
Vol 111 (4) ◽  
pp. e23-e24
Author(s):  
L. Sekhon ◽  
Z. Luscher ◽  
T.A. Cacchione ◽  
J.A. Lee ◽  
T. Mukherjee ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Assisted Reproductive Technology ◽  
Ovarian Reserve ◽  
Reproductive Technology

scholarly journals Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients

2021 ◽  
Vol 12 ◽  
Author(s):  
Sandro C. Esteves ◽  
Hakan Yarali ◽  
Lan N. Vuong ◽  
José F. Carvalho ◽  
İrem Y. Özbek ◽  
...  
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Reserve ◽  
Ovarian Stimulation ◽  
Primary Treatment ◽  
Population Based ◽  
Reproductive Technology ◽  
Female Infertility ◽  
Prevalence Rates ◽  
Real World Data ◽  
Female Age

ObjectiveTo estimate the prevalence of low-prognosis patients according to the POSEIDON criteria using real-world data.DesignMulticenter population-based cohort study.SettingsFertility clinics in Brazil, Turkey, and Vietnam.PatientsInfertile women undergoing assisted reproductive technology using standard ovarian stimulation with exogenous gonadotropins.InterventionsNone.Main outcome measuresPer-period prevalence rates of POSEIDON patients (overall, stratified by POSEIDON groups and by study center) and the effect of covariates on the probability that a patient be classified as “POSEIDON”.ResultsA total of 13,146 patients were included. POSEIDON patients represented 43.0% (95% confidence interval [CI] 42.0–43.7) of the studied population, and the prevalence rates varied across study centers (range: 38.6–55.7%). The overall prevalence rates by POSEIDON groups were 44.2% (group 1; 95% CI 42.6–45.9), 36.1% (group 2; 95% CI 34.6–37.7), 5.2% (group 3; 95% CI 4.5–6.0), and 14.4% (group 4; 95% CI: 13.3–15.6). In general, POSEIDON patients were older, had a higher body mass index (BMI), lower ovarian reserve markers, and a higher frequency of female factor as the primary treatment indication than non-POSEIDON patients. The former required larger doses of gonadotropin for ovarian stimulation, despite achieving a 2.5 times lower number of retrieved oocytes than non-POSEIDON patients. Logistic regression analyses revealed that female age, BMI, ovarian reserve, and a female infertility factor were relevant predictors of the POSEIDON condition.ConclusionsThe estimated prevalence of POSEIDON patients in the general population undergoing ART is significant. These patients differ in clinical characteristics compared with non-POSEIDON patients. The POSEIDON condition is associated with female age, ovarian reserve, BMI, and female infertility. Efforts in terms of diagnosis, counseling, and treatment are needed to reduce the prevalence of low-prognosis patients.

In Vitro Fertilization

2018 ◽  
Author(s):  
Jessica R Zolton ◽  
Rhea Chattopadhyay ◽  
Alan H. DeCherney
Keyword(s):  
In Vitro Fertilization ◽  
Assisted Reproductive Technology ◽  
Ovarian Reserve ◽  
Intracytoplasmic Sperm Injection ◽  
Reproductive Technology ◽  
Gonadotropin Releasing Hormone ◽  
The Body ◽  
Vitro Fertilization ◽  
Releasing Hormone

Assisted reproductive technology (ART) encompasses all procedures that manipulate the oocytes, sperm, and embryos outside of the body. Decades of research have allowed the field to emerge as a reliable and safe treatment for infertile men and women. Indications for in vitro fertilization (IVF) include tubal factor infertility, anovulation, male factor infertility, and decreased ovarian reserve. Treatment is not limited to the infertile population, as IVF with preimplantation genetic diagnosis also offers patients an opportunity to prevent transmission of a genetic condition for which they have been found to carry. The field of ART continues to rapidly evolve, as more knowledge is gained from studies reporting on ovarian stimulation protocols, reproductive techniques such as intracytoplasmic sperm injection, and blastocyst transfer. Techniques are aimed to improve live birth rates while ensuring the optimal health of children conceived using IVF. This review contains 8 figures, 5 tables and 63 references Key Words: assisted reproductive technology, blastocyst, decreased ovarian reserve, embryo transfer, gonadotropin-releasing hormone agonist, gonadotropin-releasing hormone antagonist, intracytoplasmic sperm injection, luteal phase support, ovarian hyperstimulation syndrome, vitrification

scholarly journals Methotrexate does not affect ovarian reserve or subsequent assisted reproductive technology outcomes

2016 ◽  
Vol 33 (5) ◽  
pp. 647-656 ◽  
Author(s):  
Christina E. Boots ◽  
Micah J. Hill ◽  
Eve C. Feinberg ◽  
Ruth B. Lathi ◽  
Susan A. Fowler ◽  
...  
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Reserve ◽  
Reproductive Technology

scholarly journals STUDY OF ANTIMULLERIAN HORMONE (AMH) LEVEL VARIATION IN FEMALES IN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) CENTRE

2020 ◽  
Vol 4 (9) ◽  
Author(s):  
Supeeti Gupta ◽  
VDS Jamwal ◽  
B Subhash ◽  
K Mohanlal
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Reserve ◽  
Prospective Observational Study ◽  
Tertiary Care ◽  
Ovarian Response ◽  
Controlled Ovarian Hyperstimulation ◽  
Reproductive Technology ◽  
Antimullerian Hormone ◽  
Antimüllerian Hormone ◽  
First Time

Study of AMH levels of patients of ART Centre and its variations has clinical relevance in the field of assisted reproductive technology. Diminished ovarian reserve has become a major cause of infertility. Anti-Mullerian hormone (AMH) seems to be a promising candidate to assess ovarian reserve and predict the response to controlled ovarian hyperstimulation (COH).  The study is a prospective, observational study carried in Department of Anatomy in collaboration with Assisted Reproductive Technology centre at a tertiary care teaching hospital. The study is carried out on eighty females who had reported to ART centre for treatment for the first time, because of involuntary childlessness with at least 1 year of unprotected intercourse without pregnancy.  In our study, eighty females were divided into four groups depending upon their AMH levels. The number of oocytes collected from each female on the day of oocyte pickup was documented. Comparison with previous studies was done. Knowledge of AMH levels will help gynaecologist to counsel the infertility patient prior to initiation of the IVF cycle. It not only allows the quantification of ovarian reserve but also predict the eventual ovarian response to ovarian stimulation and the clinical pregnancy. Keywords: AntiMullerian Hormone, Assisted Reproductive Technology, Ovarian Reserve

Sign in / Sign up

Export Citation Format

Share Document